Financial terms of the multi-year subscription were not disclosed.

The BioExpress(TM) Module consists of gene expression and associated information from a broad range of normal and diseased human tissues, tissues from model animal systems, and human and animal cell lines for use in drug target identification and drug target validation studies.

The subscription agreement provides for broad deployment of the BioExpress(TM) content, as well as the GeneExpress(R)' related GX2000(TM) data mining and analysis software tools, across Genentech's global research and development infrastructure.

"Biotechnology and pharmaceutical companies are aggressively seeking ways to increase the speed by which they identify and prioritize drug targets. The GeneExpress(R) Suite and its accompanying software tools offer a solution that we believe will become an indispensable tool for achieving these goals," said Mark D. Gessler, President and CEO of Gene Logic. "We are very pleased to form this business relationship with Genentech. Establishing an agreement with one of the pioneers of the biotechnology industry is an important validation of the strength of the GeneExpress(R) Suite and our other gene expression-based product offerings."

Gene Logic Inc. Overview

Gene Logic Inc. is a leading provider of genomic information, enabling the discovery and development of pharmaceutical, biotechnology, health care, and life science products through the systematic and industrialized application of genomics and bioinformatics. Gene Logic has built and is commercializing the world's most comprehensive survey of gene expression in human and animal tissues.

Gene expression, which is the degree to which genes in a cell are switched on or off, or regulated, is information critical to understanding the functions of genes. Gene Logic markets a growing array of gene expression-based products to the global pharmaceutical, biotechnology, health care and life science industries.

Our flagship product, the GeneExpress(R) Suite, can be used to discover and validate novel drug targets, develop and prioritize therapeutic compounds and facilitate clinical trials and patient management.

Today, a number of pharmaceutical and biotechnology companies uses Gene Logic's various gene expression products for drug discovery, predictive toxicology and diagnostic applications. For more information about Gene Logic, visit the company's Web site at www.genelogic.com or telephone toll-free on 1/800/GENELOGIC.

All statements in this press release that are not historical are considered forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Gene Logic's "expectations," "beliefs," "goals," "hopes," "strategies," or the like.

Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Gene Logic from those projected, including, but not limited to, risks and uncertainties relating to technological approaches, product development, production, market acceptance, cost and pricing of Gene Logic products, utility of genomic information in drug discovery and development, dependence on collaborative partners, sole source suppliers, competition, ability to sign new subscribers, customer renewals and terminations, intellectual property of Gene Logic and others, and patent protection and litigation.

These and other risk factors are discussed in Gene Logic's Annual Report on Form 10-K for the year ended December 31, 1999 and Gene Logic's other SEC reports, including its Quarterly Reports on Form 10-Q.

Gene Logic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Gene Logic's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.